Algerian pharmacy chain Sidall has responded to a decision by the National Social Security Fund for Wage Earners (CNAS) to suspend the third-party payment system at its pharmacies. In a press release, Sidall stated that its retail pharmacy operations are based on solid legal, administrative, and institutional foundations. The company emphasized that its activities are grounded in a license issued by the Ministry of Health on December 27, 1997, which remains in effect.
Sidall's operations are also supported by decisions from the Council of State Shareholders, particularly decision number 05/197/11/01/2025. This decision entrusted Sidall with managing the former ENDIMED institution, including its assets and license to operate. The company stressed that its license has not been revoked or expired, as the 2018 Health Law did not provide for its cancellation or renewal.
The CNAS decision to suspend the third-party payment system has prompted Sidall to engage with relevant authorities to clarify the legal and regulatory aspects of its operations. The company aims to find solutions that will allow the payment system to resume, ensuring that insured individuals are not adversely affected and can continue to access medication and pharmacy services.
Sidall reassured that its efforts focus on protecting the social rights of insured individuals and maintaining their access to essential services. The company remains committed to operating within the bounds of existing laws and regulations. Sidall's management expressed its willingness to engage in institutional dialogue and coordination with relevant authorities.
The company's press release highlighted its dedication to ensuring continuity of services through constructive engagement with stakeholders. Sidall's operations have been a cornerstone of Algeria's healthcare landscape for decades, providing vital pharmacy services to citizens. The company's commitment to compliance and cooperation underscores its role as a trusted healthcare provider.
Sidall's response to the CNAS decision reflects its proactive approach to addressing challenges and finding mutually beneficial solutions. The company's history of collaboration with regulatory bodies and stakeholders has enabled it to navigate complex healthcare issues effectively. Sidall's focus on patient care and access to medication remains unwavering.
As the situation unfolds, Sidall's engagement with CNAS and other stakeholders will be crucial in determining the future of its operations. The company's emphasis on transparency, compliance, and patient-centric care will likely play a significant role in resolving the dispute. Sidall's legacy as a reputable pharmacy chain in Algeria is built on its commitment to delivering high-quality services.
Key points
- Sidall's operations are grounded in a valid license issued by the Ministry of Health in 1997.
- The company's activities are supported by decisions from the Council of State Shareholders.
- Sidall is engaged in dialogue with authorities to resolve the CNAS payment suspension issue.
